223 results about "Foot hand mouth disease" patented technology

The invention discloses application of Chinese medicinal composition in preparation of medicament for treating hand-foot-and-mouth disease. The Chinese medicinal composition comprises weeping forsythiae capsule, honeysuckle flower, ephedra herb, bitter apricot seed and the like. The Chinese medicinal composition has the function of broad-spectrum anti-virus, and can effectively treat hand-food-and-mouth disease by effectively killing virus, eclipsing fever and diminishing inflammation.

The invention discloses a univalent and bivalent gene engineered subunit vaccine for preventing Enterovirus 71 (EV71) and Coxsackie virus A16 (Cox.A16) of hand-foot-and-mouth disease, and a preparation method thereof. The preparation method comprises the following steps: respectively obtaining recombinant baculovirus Bac-EV71-P1-3CD and Bac-Cox.A16-P1-3CD by gene engineering means, respectively efficiently coexpressing similar SeQ ID No.1 EV71 P1 and Se Q ID No.2 Cox.A16 P1 and 3CD proteins in insect cells, and respectively self-assembling into EV71 VLP and Cox.A16 VLP; establishing and verifying a vaccine strain third-stage seed lot library; culturing cells; inoculating and propagating virus; lysing the cells, ultra-filtering and purifying virus suspension; and further preparing the univalent and bivalent vaccine. The vaccine has good application prospect for preventing the hand-foot-and-mouth disease.

The invention discloses an ALD derivative or pharmaceutically acceptable salts thereof, and further provides application of the ALD derivative or the pharmaceutically acceptable salts thereof as EV71 virus and CAV16 virus inhibitors and application of the ALD derivative or the pharmaceutically acceptable salts thereof in preparing medicines for treating hand-foot-and-mouth diseases. The structural formula of the ALD derivative is as shown in the specification. The invention further provides a method for preparing the ALD derivative or the pharmaceutically acceptable salts thereof.

The invention belongs to the field of biomedicine, and provides a method for determining a cross antigen region initiating human antigens in human enterovirus 71-type (EV71) total protein. In the method, the human enterovirus 71-type total protein is identified through segmental expression; and cross reaction between immunogenic and inductive antibodies and the human antigens in each segment is performed, and different segments of the human enterovirus 71-type total protein are divided into three classes: (1) strongly-crossed immunogens initiating the human antigens; (2) weakly-crossed immunogens initiating the human antigens; and (3) no crossed immunogens existing between the antibodies and the human antigens. Thus, the method plays a guidance role in developing and preparing human enterovirus 71-type vaccines, and hand-foot-and-mouth disease vaccines having no cross reaction or weak cross reaction with human bodies can be designed according to the method.

The invention discloses a preparation method for a recombinant coxsackie virus A16 like particle, which comprises the following steps: (1) cloning a P1 gene and a 3CD gene of a coxsackie virus A16 to a target plasmid to obtain a recombinant expression vector; (2) transforming a target yeast cell by using the recombinant expression vector obtained in the step (1) to obtain a recombinant yeast cellfor expressing the P1 gene and the 3CD gene; and (3) cracking the recombinant yeast cell obtained in the step (2), and separating to obtain the recombinant coxsackie virus A16 like particle. The recombinant coxsackie virus A16 like particle can be prepared in a yeast expression system by the method provided by the invention. Compared with a wild-type P1 gene and a wild-type 3CD gene, the yield ofthe coxsackie virus A16 like particle in the yeast expression system is greatly increased through the optimization of codons of the P1 gene and the 3CD gene, and the recombinant coxsackie virus A16 like particle can be further used for producing candidate preventive vaccines and pharmaceutical compositions for infant hand-foot-and-mouth diseases.

The present invention relates to the technical field of clinical medicine, and particularly to a medical record processing method, apparatus and system. The method comprises: acquiring medical record data of a current patient; performing an operation on the medical record data by using a pre-established symptom stage model, wherein the symptom stage model is established in advance according to medical record data of multiple patients whose disease stage has been determined; determining a disease stage of the current patient according to a result of the operation; and displaying the disease stage of the current patient. According to the method, by means of the symptom stage model, the operation is performed on the medical record data of the current patient to determine the disease stage of the patient, so that the doctor only needs to directly acquire the medical data of the patient in clinical medical treatment and determine the disease stage of the patient, i.e. a development stage of the hand-foot-and-mouth disease by combining actual situations after seeing the displayed disease stage of the current patient, which reduces hand-foot-and-mouth disease condition delay in clinic.

The invention provides an agarose compatible medium for purifying immune globulin of the hand-foot-and-mouth disease and a preparation method thereof. In the agarose compatible medium, agarose gel is used as a matrix, is activated by an epoxy activating agent, and is coupled with vaccine of the hand-foot-and-mouth disease which is used as petunidin, wherein the agarose gel is made of one of agarose 6FF, agarose 4FF, agarose CL-6B, agarose CL-4B, agarose 6B and agarose 4B. The agarose compatible medium can be used for purifying the immune globulin of the hand-foot-and-mouth disease, has the advantages of good medium selectivity, strong specificity, strong mechanical strength and industrial amplification benefit. Furthermore, the preparation process is simple and is easy to amplify. The medium prepared by the method is adopted for purifying the immune globulin of the hand-foot-and-mouth disease, and has simple and feasible purification method and good separation effect.

The present invention concerns the manufacture of EV71 acceptor SCARB 2 transgenic mouse. The manufactured SCARB 2 transgenic mouse can be used as an animal model infected with the hand-foot-and-mouth disease, such as infected with enterovirus 71 or Coxsackies virus A16, so as to allow for estimation of enterovirus viral vaccine immune protection efficacies and application of enterovirus infection in pathological study.

The invention discloses an underreporting preventing management system and method for notifiable infectious diseases such as hand-foot-and-mouth diseases, influenza and the like. The system comprises three major functional modules of an information automatic acquisition module, a notifiable infectious disease automatic interception and reporting module and a notifiable infectious disease underreporting automatic check module. The underreporting preventing management method for the notifiable infectious diseases such as the hand-foot-and-mouth diseases, the influenza and the like comprises the following steps of automatically acquiring information: registering outpatient logs, forming notifiable infectious disease electronic report cards, forming notifiable infectious disease report cards, registering admission and discharge, and registering abnormal check results; and calling a hospital HIS to form electronic outpatient logs by utilizing an outpatient log registration module, wherein data acquisition sources are registration office information in the HIS, outpatient doctor workstation information, clinic electronic medical record information, electronic medical record information of an inpatient department and the like.

The invention relates to a Chinese medicament for treating hand-foot-and-mouth diseases, and belongs to the technical field of medicaments. The Chinese medicament is prepared into a decoction from the following raw materials: 3 to 10 g of licorice, 3 to 10 g of folium isatidis, 5 to 15 g of isatis root, 1 g of coptis, 3 to 10 g of tee tree root, 3 to 10 g of bupleurum, 3 to 10 g of dandelion, 3 to 10 g of mint, 3 to 10 g of Chinese violet, 5 to 10 g of dried rehmannia root, 5 to 10 g of honeysuckle, 5 to 10 g of weeping forsythia, 5 to 10 g of pseudostellaria heterophylla, 5 to 10 g of root of red-rooted salvia, 5 to 10 g of honeysuckle stem, 3 to 5 g of phellodendron, 3 to 6 g of gardenia, 3 to 10 g of figwort root, and 3 to 5 g of big fritillaria. Based on the cognition and the treatment principle of the pathogenesis of the hand-foot-and-mouth diseases, the Chinese medicament is prepared by using the traditional Chinese medicinal materials as raw materials through clinical test and repeated verification; and the Chinese medicament emphasizes heat clearing, detoxification and dehumidification, simultaneously proposes tonification and purgation in combination, qi tonification, yin nourishment, heat clearing and collateral dredging, accords with the theory of the traditional Chinese medicine, avoids the side response of unidirectional action of the western medical therapy and does not have toxic or side effect, the effective rate is 98 percent, and the cure rate is over 95 percent.

The invention discloses a method for preparing an indoor air virus pathogen invincible opponent. The indoor air virus pathogen invincible opponent prepared by menthol, thymol, weeping forsythia oil and radix bupleuri oil has the killing rate of between 76 and 99.9 percent to idemic encephalitis, influenza viruses, hand-foot-and-mouth disease, avian influenza, legionnella, pneumoniae, hepatitis C viruses, hepatitis A viruses, Staphylococcus albus, Staphylococcus aureus, Klebsiella pneumoniae, Candida albicans, typhoid viruses, Escherichia coli, cholera viruses, infectious germs and bacteria, and harmful germs and bacteria. The indoor air virus pathogen invincible opponent is mainly applied to rooms, schools, hospitals, hotels, air conditioners, automobiles, public places, and the like, and has obvious effect on the control of diseases such as influenza, upper respiratory tract infection. The indoor air virus pathogen invincible opponent has outstanding substantive characteristics and broad application prospect.

The invention relates to the pharmacy field, concretely relates to a use of a series of pentacyclic triterpene compounds as enterovirus EV71 inhibitors, and especially relates to an application in the preparation of medicines for preventing and treating EV71 infection induced hand-foot-and-mouth diseases and complications thereof, such as synanche, myocarditis, pulmonary edema, encephalitis, herpes, septicemia, hypertension, hyperglycemia, cognitive function disorder, poliomyelitis-like paralysis and many nerve system associated diseases. The invention also discloses medicinal compositions of the series of the pentacyclic triterpene compounds as enterovirus EV71 inhibitors.

The invention discloses a method for testing the quality of antiviral oral liquid for treating the hand-foot-and-mouth disease and relates to the technical field of medicaments. In the method for testing the quality, the quality is tested by using a high performance liquid chromatogram single-test multi-evaluation method. 10 ml of antiviral oral liquid contains no less than 60 mu g of (R,S)-goitrin, no less than 1 mg of forsythoside A, no less than 0.25 mg of forsythin and no less than 0.12 mg of forsythingenin. The method has the advantages that: the method is simple and convenient; the content of four active ingredients of the antiviral oral liquid can be tested at the same time; the quality of the antiviral oral liquid and the curative effect of the antiviral oral liquid on the hand-foot-and-mouth disease can be comprehensively evaluated by establishing a quantitative analysis result of the active ingredients of the antiviral oral liquid, so the antiviral oral liquid has a truly-controllable standard; and simultaneously, the medicinal material basis of a Chinese medicinal preparation, namely, the antiviral oral liquid in the aspect of curing the hand-foot-and-mouth disease is put forward in China for the first time.

The invention provides a fluorescence quantitative RT-PCR detecting kit for an enterovirus and a detecting method thereof; and the sequences of an upstream primer and a downstream primer and a specific probe of the fluorescence quantitative RT-PCR detecting kit are as follows: the upstream primer EV(YG)F is 5'-GGCTGCGYTGGCGGCC-3', the downstream primer EV(YG)R is 5'-CCAAAGTAGT CGGTTCCGC-3' and the specific probe EV(YG)PB is 5'-CTCCGGCCCCTGAATGCGG-3'. The method has high specificity on detecting the enterovirus and does not have cross reactions with other enteroviruses such as hepatitis A, hives, rubella, parotitis, encephalitis, dengue fever, adenovirus, and the like. The detection sensitivity of the method achieves 0.1TCID50; the method can directly detect the nucleic acid of the enterovirus from the samples of ncurolymph, herpes liquid, dejecta and the like of suspected patients; only about 3h is needed from extracting the nucleic acid of the enterovirus to finishing the detection; and the detecting kit and the detecting method are suitable for the lab early diagnosis of sudden epidemic caused by the infection of the enteroviruses such as the hand-foot-and-mouth disease and the like.

The invention discloses a gene recombinant vaccine for preventing enterovirus 71 (EV71) infection and a preparation method thereof. The inflection comprises multiple diseases related with the nervous system such as hand-foot-and-mouth disease, paralytic diseases of sterile meningitis, cephalitis and poliomyelitis and the like. Escherichia coli labile enterotoxin B subunit (LTB) is used as an immunological enhancement adjuvant, two fragments of linear neutralizing epitope SP55 and SP70 in EV71 virus coat protein VP1 are used as antigens, prokaryotic expression plasmids of LTB-SP55-SP70 fusion genes are constructed by using gene engineering technology, the plasmids are expressed in escherichia coli, and a recombinant expression product is purified for preparing the EV71 virus gene engineering vaccine.

The invention discloses new application of scullcapflavone in preparing a medicament for treating enterovirus infection, in particular new application of scullcapflavone in preparing a medicament for treating or preventing a hand-foot-and-mouth disease caused by enterovirus infection. The scullcapflavone comprises an extract of baicalein, baicalin or scutellaria baicalensis general flavone; and the enterovirus indicates a coxsackie virus A group, a coxsackie virus B group, echovirus or enterovirus EV71 which causes the hand-foot-and-mouth disease. The scullcapflavone as an active substance is mixed with a pharmaceutically allowable excipient and made into a preparation which can be accepted by a patient and can be used for treating and preventing the hand-foot-and-mouth disease by injection administration, mucosa administration, oral administration or inhalation and has obvious treating effect and high safety.

The invention relates to EV71 virus-like particles and hand-foot-and-mouth disease vaccine prepared from the EV71 virus-like particles. The EV71 virus-like particles are prepared according to the following steps: (1) constructing recombinant plasmid: respectively connecting pGAPZ alpha A plasmid with P1 protein gene of intestinal EV71 virus and 3CD protease gene to construct P1-pGAPZ alpha A and 3CD-pGAPZ alpha A recombinant plasmid; (2) transferring the recombinant plasmid to expression bacterial strains: sequentially transferring the recombinant plasmid to Pichia pastoris SMD1168 expression bacterial strains to obtain P1-pGAPZ alpha A-3CD-pGAPZ alpha A-SMD1168 recombinant expression strains; and (3) culturing thallus and purifying the EV71 virus-like particles: culturing the Pichia pastoris recombinant expression bacterial strains, centrifugalizing to separate supernate, and carrying out sucrose density gradient centrifugation on precipitation of the supernate after ultracentrifugation, thus obtaining the EV71 virus-like particles. In the invention, the EV71 virus-like particles are easy to obtain through thallus culture, have good stability, are easy to purify and suitable for preparing vaccine, and are convenient for industrial production.

The invention provides a drug curtain cloth preventing influenza A H1N1 and a preparation method. Traditional Chinese medicine solution is utilized to perform after-treatment processing on curtain textile and causes the curtain textile to be hung indoors to bring the effects of preventing influenza A H1N1, hand-foot-and-mouth disease, SARS and the like. The drug curtain cloth preventing influenza A H1N1 comprises a drug curtain cloth which is padded and fixed with wrinkled giant hyssop, folium artemisiae argyi, litsea cubeba and rhizoma kaempferiae solution ingredients and is dried and fixed on the curtain textile. The drug curtain cloth of the invention has the following advantages: 1) the drug curtain cloth can effectively prevent epidemics such as influenza A H1N1, hand-foot-and-mouth disease, SARS and the like; 2) Chinese herbal medicine adopts nano-scale micro-particle polyacrylic ester emulsion and can realize crosslinking without high-temperature curing, and operation is simple and easy to operate and can be realized in industrial production; 3) the drug curtain has no harm on human bodies, can clean air and make bodies fit, and has the function of Chinese herbal medicine, and the drug curtain cloth of the invention can be popularized and applied in the market of curtain and decoration fabric; and 4) the drug curtain cloth of the invention resists high temperature and washing and has great practical value.

The invention relates to the field of biomedicine, and specifically relates to an enterovirus 71 antigen detection test strip (colloidal gold method) and a preparation method and application thereof. Enterovirus 71 can cause hand-foot-and-mouth disease, which has largegeneration proportion of severe infections (viral encephalitis, meningomyelitis virus and pulmonary edema), and a high death rate reaching 10%-25%. The test strip of the invention is used for rapid diagnosis of EV(enterovirus)71 infection. A virus separation and an RT-PCR (reverse transcription-polymerase chain reaction) are methods first used for EV71 antigen detection, but are not suitable for primary clinic usage due to defects of difficult operation and high costs, etc. The invention overcomes the above insufficiencies and provides a reagent, which is highly demanded in clinic detection, simply operated, suitable for various medical disease control sections, and capable of detecting EV71 antigens in human oropharyngeal swabs, bubble liquid, serum or excrement, and also provides the preparation method and application thereof. A technical scheme is as follows: a specimen is dropped on a sample pad, and the EV71 antigen wherein combines with a gold-labeled EV71 polyclonal antibody in a gold-labeled pad and migrates along a chromatography membrane. A detected line captures colloidal gold particles to form a red line visible to naked eyes, so as to realize detection of the EV71 antigen.

The invention relates to a new drug using present antibiosis and antiphlogosis drug andrographolide and its derivative to prevent and treat the hand-foot-and-mouth disease, and provides a new uses of andrographolide drugs. The invention concretely relates to a use of the andrographolide drugs in the preparation of drugs for preventing and/or treating hand-foot-and-mouth disease virus infection. Pharmacodynamics researches on the andrographolide drugs, such as andrographolide, neoandrographolide, sulfonated andrographolide, triacetyl andrographolide and dehydroandrograpolide succinate show that andrographolide and its derivative are high efficiency drugs for preventing and treating the hand-foot-and-mouth disease, can be processed to prepare various common dosage forms used for clinical prevention and treatment, and have the characteristics of good curative effect, low toxicity and low price. A new drug is provided for the prevention and treatment of clinic hand-foot-and-mouth disease patients, and important bases are provided for finding a new theory and a new drug action target.

The invention belongs to the field of medicaments, discloses application of lycorine, lycorine salt, lycorine hydrate, lycorine optical isomer or lycorine prodrug in preparing medicaments for treating diseases caused by human enterovirus 71 type infection, preferably treating hand-foot-and-mouth disease, herpangina, viral meningitis, viral encephalitis, flaccid paralysis, pulmonary edema and vital myocarditis. In vitro and in vivo tests prove that the lycorine can inhibit replication and lesion of enterovirus (EV) 71 in cells, has excellent function of inhibiting the EV 71 virus, and has clinical application prospect.

The invention provides an intestinal tract virus EV71 fluorescence RT-PCR detection kit and a detection method applied to the emergency detection in a hand-foot-and-mouth disease laboratory. The primer and the probe sequences of the fluorescent quantitation RT-PCR detection kit are: EV 71 YG F1:5'-TGA TTGAGACACGC/GTGTGTT/CCTTA-3'; EV71 YG R1:5'-CCCGC TCTGCTGAAGAAACT-3'; and EV71YG pb 1:5'-TCGCACAGCACA GCTGAGACCACTC-3'. The method has high degree of specificity on the detection of the intestinal tract virus EV71 and does not have cross reaction with virus such as CA16, CA4, CA21, E6, E30, CoxB5 and POLIO. The detection sensitivity of the method is up to 0.1TCID50. The method can detect the intestinal tract virus EV71 nucleic acid directly from the samples such as the ncurolymph, the herpes fluid and the night soil of the suspect patient with the hand-foot-and-mouth disease. The process from extracting the nucleic acid from the virus to completing the detection only needs three hours.

The invention discloses a composition used for detecting enterovirus causing hand foot and mouth disease, which comprises an upstream primer P1:5'-CCCTGAATGCGGCTAATCC-3' and a downstream primer P2:5'-GTCGGTTCCGCTGCAGAGT-3'. Genetic fragments of 5'UTR regions of EV71 and Cox A16 type enteroviruses in a sample can be specifically detected by the composition matched with a proper probe and other reagents through a real time Polymerase Chain Reaction (PCR) method. The invention also discloses a kit containing the composition, and a method for detecting the EV71 and/or Cox A16 type enterovirus by utilizing the composition or the kit. When the composition or the kit and/or the method is utilized for detecting the sample, whether the EV71 and/or Cox A16 type enterovirus exist in the sample can be sensitively and rapidly detected in a reaction; therefore, the efficiency and the sensitivity of the detection are improved, the detection process is simplified, and the manpower, the material resources and the detection cost are saved.